Registry of Lobbyists

Registration - In-house Organization

Canadian Generic Pharmaceutical Association (CGPA) / L'Association canadienne du médicament générique (ACMG) / JAMES KEON, PRESIDENT

Registration Information

In-house Organization name: Canadian Generic Pharmaceutical Association (CGPA) / L'Association canadienne du médicament générique (ACMG)
Previous in-house organization names
Responsible Officer Name: JAMES KEON, PRESIDENT 
Initial registration start date: 1998-07-22
Registration status: Active
Registration Number: 776966-548

Associated Communications

Total Number of Communication Reports: 364

Monthly communication reports in the last 6 months: 8

Version 1 of 51 (1998-07-22 to 1999-01-28)

Version 1 of 51 (1998-07-22 to 1999-01-28) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.

A. Organization Information

Organization: CANADIAN GENERIC PHARMACEUTICAL ASSOCIATION (CGPA)
409 - 4120 YONGE STREET
NORTH YORK, ON  M2P 2B8
Canada
Telephone number: 416-223-2333
Fax number: 416-223-2425  
Responsible officer name and position during the period of this registration: JAMES KEON, PRESIDENT  
 
Description of the organization's activities: THE CANADIAN DRUG MANUFACTURERS ASSOCIATION'S MISSION IS TO PROMOTE AN ENVIRONMENT WHICH SUPPORTS AND ENHANCES THE PROVISION OF AFFORDABLE GENERIC MEDICATIONS TO CANADIANS AND PATIENTS AROUND THE WORLD THROUGH RESEARCH, DEVELOPMENT AND MANUFACTURING OF PHARMACEUTICALS AND FINE CHEMICALS IN CANADA.
Organization's membership or classes of membership: THE CDMA IS COMPOSED OF 21 MEMBER COMPANIES IN THE GENERIC AND BIOPHARMACEUTICAL INDUSTRY, FINE-CHEMICAL COMPANIES AND FINAL DOSAGE COMPANIES.
 
Was the organization funded in whole or in part by any domestic or foreign government institution in the last completed financial year? No
 

B. Lobbyists Employed by the Organization

Name: JAMES KEON
Position title: PRESIDENT
Public offices held: N/A. Disclosure of this information was not a requirement prior to June 20, 2005.
 
Name: PAULA REMBACH
Position title: RESEARCH ANALYST
Public offices held: N/A. Disclosure of this information was not a requirement prior to June 20, 2005.
 
Name: JULIE TAM
Position title: DIRECTOR, PROFESSIONAL & SCIENTIFIC AFFAIRS
Public offices held: N/A. Disclosure of this information was not a requirement prior to June 20, 2005.
 

C. Lobbying Activity Information

Federal departments or organizations which have been or will be communicated with during the course of the undertaking: Canadian International Development Agency (CIDA), Canadian International Trade Tribunal (CITT), Competition Tribunal (CT), Environment Canada, Federal Office of Regional Development – Quebec (FORD[Q]), Finance Canada (FIN), Foreign Affairs and International Trade Canada (DFAITC), Hazardous Materials Information Review Commission (HMIRC), Health Canada (HC), Human Resources Development Canada (HRDC), Industry Canada, Justice Canada (JC), National Research Council (NRC), Natural Sciences and Engineering Research Council (NSERC), Patented Medicine Prices Review Board (PMPRB), Privy Council Office (PCO), Revenue Canada (RC), Statistics Canada (StatCan), Treasury Board Of Canada Secretariat (TBS), Western Economic Diversification Canada (WD)
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Grass-roots communication, Informal communications, Meetings, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format
 
Subject Matter: Areas of Concern: Consumer Issues, Health, Industry, Intellectual Property, Internal Trade, International Relations, International Trade, Science and Technology, Small Business, Taxation and Finance
 
Subject Matter: Retrospective: DISCUSSIONS WITH THERAPEUTICS PRODUCTS PROGRAMME OF HEALTH CANADA AND INDUSTRY CANADA RE: ONGOING EXCHANGE OF MATERIAL RE: PATENT RESTRICTIONS IN GENERIC PHARMACEUTICAL EXPORTS; PATENT ACT - DISCUSSION WITH GOV'T OFFICIALS RE: PMPRB (PATENTED MEDICINE PRICES REVIEW BOARD) - ONGOING REVIEW OF NOTICE OF COMPLIANCE REGULATIONS - BRIEFS TO GOV'T ON REGULATORY APPROVAL PROCESS FOR GENERIC MEDICINES.
Subject Matter: Prospective: INTERPRETATION & APPLICATION OF TRADE AGREEMENTS WITH THE GENERIC RX INDUSTRY, E.G. CHALLENGE OF CANADA'S PATENT ACT BY EU - CONTINUATION OF NOC REGULATIONS, PATENT ACT, ANTI COMPETITIVE BEHAVIOUR, DRUG REGULATORY REVIEWN PROCESS.




Date Modified: